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Background: 6-Hydroxydopamine (6-OHDA) is widely used in pre-clinical animal studies to induce degeneration of
midbrain dopamine neurons to create animal models of Parkinson's disease. The aim of our study was to evaluate
the potential of combined single-photon emission computed tomography/computed tomography (SPECT/CT) for
the detection of differences in 6-OHDA-induced partial lesions in a dose- and time-dependent manner using the
dopamine transporter (DAT) ligand 2β-carbomethoxy-3β-(4-[123I]iodophenyl)tropane ([123I]β-CIT).
Methods: Rats were unilaterally lesioned with intrastriatal injections of 8 or 2 × 10 μg 6-OHDA. At 2 or 4 weeks
post-lesion, 40 to 50 MBq [123I]β-CIT was administered intravenously and rats were imaged with small-animal
SPECT/CT under isoflurane anesthesia. The striatum was delineated and mean striatal activity in the lesioned side
was compared to the intact side. After the [123I]β-CIT SPECT/CT scan, the rats were tested for amphetamine-induced
rotation asymmetry, and their brains were immunohistochemically stained for DAT and tyrosine hydroxylase (TH).
The fiber density of DAT- and TH-stained striata was estimated, and TH-immunoreactive cells in the rat substantia
nigra pars compacta (SNpc) were stereologically counted.
Results: The striatal uptake of [123I]β-CIT differed significantly between the lesion groups and the results were
highly correlated to both striatal DAT- and TH-immunoreactive fiber densities and to TH-immunoreactive cell
numbers in the rat SNpc. No clear progression of the lesion could be seen.
Conclusions: [123I]β-CIT SPECT/CT is a valuable tool in predicting the condition of the rat midbrain dopaminergic
pathway in the unilateral partial 6-OHDA lesion model of Parkinson's disease and it offers many advantages,
allowing repeated non-invasive analysis of living animals.
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The main feature of Parkinson's disease (PD) is dege-
neration of the nigrostriatal dopaminergic neurons,
resulting in motor symptoms such as resting tremor,
posture instability, rigidity, and bradykinesia [1]. The
neurotoxin 6-hydroxydopamine (6-OHDA) is widely
used in a well-established rat model of PD to mimic the
midbrain dopaminergic degeneration seen in the disease* Correspondence: susanne.back@helsinki.fi
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in any medium, provided the original work is p[2-5]. The extent of the lesion is dependent on the
6-OHDA injection site as well as on the dose of 6-
OHDA [6,7]. When injected intrastriatally, 6-OHDA
causes immediate damage to the dopaminergic fibers in
the striatum followed by a retrograde progressive loss of
dopaminergic cell bodies in the substantia nigra pars
compacta (SNpc) [8]. This rat partial lesion model of PD
is widely used in pre-clinical studies since the progres-
sive dying back of the dopamine neurons provides
a time window that allows for testing of potentially
neuroprotective agents.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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and efficacy of treatments in living animals as a function
of time. Conventionally, this is done by monitoring
motor functions with behavioral tests or by invasive
methods, such as in vivo microdialysis. To do more ex-
tensive evaluation of the dopaminergic system, endpoint
tissue analyses usually need to be applied. In vivo
imaging of 6-OHDA-lesioned rats with single-photon
emission computed tomography/computed tomography
(SPECT/CT) offers a considerable potential for monitor-
ing changes in the midbrain dopaminergic pathway
allowing longitudinal studies in living animals.
In this study, we used the high-affinity dopamine
transporter (DAT) radioligand 2β-carbomethoxy-3β-
(4-[123I]iodophenyl)tropane ([123I]β-CIT) [9,10] to esti-
mate the DAT density in the rat striatum in unilaterally
6-OHDA-lesioned rats. DAT is responsible for the ter-
mination of dopamine signaling by re-uptake of dopa-
mine from the synaptic cleft [11]. In the CNS, the
transporter is found only in the plasma membrane of
dopamine neurons [12] which makes it an excellent
marker of this network.
To our knowledge, only a few studies examining DAT
binding with SPECT in 6-OHDA-lesioned rats have
been published [13-15]. In these studies, 6-OHDA was
administered to the rat SN [13,15] or medial forebrain
bundle (MFB) [14]. Compared to intrastriatal injections
of 6-OHDA, injections to the SN or MFB result in a
more extensive dopaminergic lesion that is almost fully
developed in less than 1 week after the injection [4,5,7].
Several studies of the rat unilateral 6-OHDA lesion
model have been conducted using positron emission
tomography (PET) cameras and tracers [16-23], but
these studies have also mainly focused on the SN or
MFB 6-OHDA lesion. Furthermore, there are very few
studies presenting data on the degree of correlation be-
tween in vivo imaging of DAT binding and immunohis-
tochemical findings. Therefore, the aim of our study was
to determine the discrimination capacity of [123I]β-CIT
SPECT/CT in terms of severity of dopaminergic lesion
and time after induction of lesion following intrastriatal
administration of 6-OHDA. We also wanted to assess
the degree of correlation between [123I]β-CIT SPECT/
CT and immunohistochemical data used for the evalu-
ation of the rat midbrain dopaminergic system in the
unilateral partial 6-OHDA lesion model of PD.
Methods
Animals and surgery
Wistar male rats (Harlan, The Netherlands) were group-
housed in a 12:12 h light/dark cycle. The rats had free
access to rodent food (Harlan) and tap water. All proce-
dures were approved by the National Animal Experi-
ment Board (ESAVI/4706/04.10.03/2011) and carriedout in accordance with the European Communities
Council Directive 86/609/EEC.
Nineteen rats (250 to 300 g) received unilateral
intrastriatal injections of 6-OHDA (6-OHDA hydro-
chloride, Sigma-Aldrich, St. Louis, MO, USA) in a
stereotaxic operation. The rats were anesthetized with
isoflurane (2% to 4%) and placed in a stereotaxic frame
(Stoelting, Wood Dale, IL, USA). After exposure of the
skull, the coordinates for single-site (1.0 mm anterior
and 2.7 mm lateral to bregma) and two-site injections
(1.6 mm anterior, 2.2 mm lateral, and 0.4 mm posterior,
4.0 mm lateral to bregma) were determined according to
the rat brain atlas of Paxinos and Watson [24]. Injec-
tions of 8 μg (single-site) or 2 × 10 μg (two-site)
6-OHDA diluted in 0.02% ascorbic acid were made 5
mm below the dura using a stereotaxic injector
(Stoelting, Wood Dale, IL, USA) and a 10-μl syringe
(Hamilton, Bonaduz, Switzerland). All injections were
done with an injection volume of 4 μl and injection
speed of 1 μl/min. After the injection, the needle was
kept in place 2 min before withdrawal to prevent reflux.
During the operation, all rats received an injection of
tramadol (1 mg/kg, s.c., Tramal, Orion Oyj, Espoo,
Finland) for post-operative pain, and the rats were
single-housed overnight. Four additional rats were left
intact and used for assessment of basal values. Intact
animals were used since in a previous small pilot study
we did not detect any change in [123I]β-CIT binding fol-
lowing sham lesion (results not shown).
SPECT/CT imaging
At 2 or 4 weeks post-lesion, the rats (290 to 350 g) re-
ceived an intravenous injection of 40 to 50 MBq [123I]β-
CIT (MAP Medical Technologies Oy, Tikkakoski,
Finland). Four hours later, the rats were imaged with
nanoSPECT/CT (Bioscan Inc., Washington, DC, USA)
featuring 2.5-mm multipinhole rat apertures. Imaging
was performed under isoflurane anesthesia (2% to 3%),
and the body temperature was maintained warm using a
heated animal bed (Minerve, France). Brain SPECT im-
ages were collected in 24 projections using time per pro-
jection of 150 s resulting in a total acquisition time of 30
min. CT imaging was carried out with a 45-kVp tube
voltage in 180 projections. SPECT images were recons-
tructed with HiSPECT NG software (Scivis GmbH,
Germany) and fused with CT datasets using InVivo-
Scope software (Bioscan Inc.). Reconstructed SPECT im-
ages were reoriented and analyzed with InVivoScope
software using CT data as a reference. Elliptical volume
of interest was defined around the striatum of an intact
rat and used in all subsequent analyses. The mean stri-
atal activity (activity-to-volume ratio) was counted and
corrected for background activity from the cerebellum.
Two of the intact rats were imaged at each time point,
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together in all subsequent analyses.
Amphetamine-induced rotations
Two days after each SPECT/CT scan, rats were injected
with D-amphetamine (2.5 mg/kg, intraperitoneally (i.p.)),
and full amphetamine-induced turns were monitored for
120 min using Rotorat software (Med Associates Inc., St.
Albans, VT, USA). The results were counted as the total
amount of net ipsilateral rotations per 120 min.
Tissue preparation and immunohistochemistry
One day after the drug-induced rotational test, rats were
anesthetized with an overdose of pentobarbital (90 mg/
kg, i.p., Mebunat, Orion Oyj, Espoo, Finland). Rat brains
were fixed by intracardial perfusion with 4% paraformal-
dehyde for 10 min. The brains were then removed and
post-fixed in 4% paraformaldehyde overnight. The rat
brains were stored in 20% sucrose at 4°C until freezing,
and frozen brains were cut on a microtome into 40-μm
sections in series of six.
Fixed free-floating sections were washed with PBS and
treated with 3% hydrogen peroxide solution. For anti-
DAT staining, the sections were incubated in 10 mM cit-
rate buffer (pH 6) at 80°C for 30 min. After incubation
in the blocking solution (2% normal horse serum or nor-
mal rabbit serum, respectively, Vector Labs, Burlingame,
CA, USA), the sections were incubated overnight in
mouse anti-tyrosine hydroxylase (TH) antibody (1:2000,
#MAB318, Millipore, Temecula, CA, USA) or rat anti-
DAT antibody (1:1000, #MAB369, Millipore). Following
incubation in biotinylated secondary antibody (1:200,
horse anti-mouse #BA2001 or rabbit anti-rat #BA4000,
Vector labs), the staining was reinforced with avidin-
biotin complex (ABC-kit, Vector Labs) and visualized
with 3′3-diaminobenzidine (Sigma-Aldrich).
Stereologic assessment of TH-reactive cells in the SNpc
The number of TH-reactive cells in the SNpc was esti-
mated with stereology using the Stereo Investigator plat-
form (MicroBrightField, Williston, VT, USA). Six nigral
sections (every sixth section) from each rat brain were
chosen (ranging from approximately 4.5 to 6.0 mm pos-
terior to bregma[24]) and the cells were counted bilat-
erally in a blinded fashion using unbiased counting rules.
Estimation of optical density of dopaminergic fibers in
the rat striatum
Optical density of TH- and DAT-stained striata was
measured using ImagePro Plus software (Media Cyber-
netics, Bethesda, MD, USA). Five pictures from the rat
striatum (ranging from approximately 1.6 to 0.2 mm
anterior to bregma, [24]) were taken with a digital cam-
era (Nikon Corporation, Tokyo, Japan) attached to astereomicroscope. The dorsal striatum was delineated
with a circle tool, and the optical density inside the area
of interest was measured. The same area of interest was
used for all sections, and all values were corrected by
subtracting the background value achieved from the cor-
tex of each section.
Statistics
All results are given as mean ± standard error of the
mean (SEM). All data were tested for normal distribu-
tion with Levene's test for homogenicity. In the case of
multiple treatment groups, the data were analyzed using
one-way analysis of variance (ANOVA) followed by
Tukey post hoc test. The effect of the 6-OHDA-induced
lesion as compared to the corresponding intact side was
tested with paired samples t test. Correlations between
measurements were tested with Pearson correlation test.
All statistical analyses were done with Pasw Statistics 18
software (SPSS, Inc., Chicago, IL, USA). A P value <0.05
was considered to be statistically significant.
Results
DAT binding of [123I]β-CIT measured with nanoSPECT/CT
Unilateral intrastriatal injection of 6-OHDA resulted in a
statistically significant decrease in the striatal [123I]β-CIT
activity (MBq/mm3) in the lesioned (left) side as compared
to the corresponding intact (right) side in all lesion groups
(paired samples t test) (Table 1; representative pictures in
Figure 1A,B). No difference in the right side [123I]β-CIT
binding was detected between the treatment groups (one-
way ANOVA (P = 0.655, F4,21 = 0.618)).
The 6-OHDA-induced changes in the striatal [123I]β-
CIT uptake (percentage of left versus right side) showed
statistically significant differences between all groups (in-
tact, 8 μg 6-OHDA, and 2 × 10 μg 6-OHDA) at both 2
and 4 weeks post-lesion (one-way ANOVA (P < 0.001,
F4,21 = 57.460) and Tukey post hoc test) (Figure 2A).
There was a decrease in striatal [123I]β-CIT activity in
the 6-OHDA-lesioned hemisphere of 18% ± 2% (at both
2 and 4 weeks) in the 8-μg 6-OHDA lesion group and
30% ± 2% (at 2 weeks) and 32% ± 2% (at 4 weeks) in the
2 × 10-μg 6-OHDA group. Thus, the decrease in DAT
binding due to the 6-OHDA-induced lesion was of the
same magnitude at both 2 and 4 weeks post-lesion.
Amphetamine-induced rotation asymmetry
Following an i.p. injection of amphetamine, no statisti-
cally significant differences in the drug-induced rota-
tional behavior could be detected between the treatment
groups (one-way ANOVA, P = 0.211, F4,22 = 1.628). At 2
weeks post-lesion, the amount of net ipsilateral rotations
per 120 min was 456 ± 207 in the 8-μg lesion group and
242 ± 119 for rats lesioned with 2 × 10 μg 6-OHDA
(n = 4 per group). At 4 weeks post-lesion, the
Table 1 Quantitative results from [123I]β-CIT SPECT/CT and TH-reactive cell counts
Intact 8 μg 6-OHDA 2 × 10 μg 6-OHDA
Left Right Left Right Left Right
Mean striatal uptake of [123I]β-CIT (×10−4 MBq/mm3) 2 weeks 2.3 ± 0.3 2.1 ± 0.3 2.0 ± 0.2* 2.6 ± 0.3 1.4 ± 0.2** 2.2 ± 0.2
4 weeks 1.7 ± 0.1** 2.2 ± 0.1 1.4 ± 0.1** 2.3 ± 0.2
TH-reactive cells in the SNpc 2 weeks 8,047 ± 1,074 8,675 ± 487 5,426 ± 586* 8,232 ± 164 2,894 ± 312** 8,328 ± 439
4 weeks 5,759 ± 640* 8,298 ± 338 2,658 ± 655** 8,239 ± 434
Striatal [123I]β-CIT binding detected with SPECT/CT and TH-reactive cell numbers in the SNpc at 2 and 4 weeks after induction of 6-OHDA-mediated degeneration
of the rat midbrain dopaminergic pathway. Unilateral injection of 6-OHDA (8 or 2 × 10 μg) to the left rat striatum resulted in a significant decrease in striatal
[123I]β-CIT uptake and nigral TH-reactive cell counts when compared to the right (intact) side. The results are given as mean ± SEM. *P < 0.05 and **P < 0.01 as
compared to the right (intact) side (paired samples t test, n = 4 to 5 per group).
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spectively (n = 5 per group). For correlations with other
results, see Table 2 and Figure 3. The intact rats showed
no turning preference (−3 ± 1 net ipsilateral turns per
120 min, n = 4).Figure 1 Representative pictures of striatal binding of [123I]β-
CIT and immunohistochemical staining with dopaminergic
markers. Striatal activity of [123I]β-CIT detected with SPECT/CT
(coronal view (A) and transversal view (B)), DAT immunoreactivity in
the striatum (C), TH immunoreactivity in the striatum (D), and nigral
TH-immunoreactive cells (E) in intact and 6-OHDA-lesioned rats
(8 and 2 × 10 μg 6-OHDA) at 4 weeks post-lesion. The orientation of
the pictures is denoted in (A) with left (L) and right (R). Scale bar in
(E) is 500 μm.Morphometric analysis of TH-reactive cell bodies in SNpc
and striatal fiber density
Intrastriatal injections of 8 and 2 × 10 μg 6-OHDA
resulted in statistically significant loss of TH-reactive
cells in the left side of the rat SNpc as compared to the
right side (paired samples t test) (Table 1; representative
pictures in Figure 1E). There was no difference in the
right side TH-reactive cell numbers between the differ-
ent groups (one-way ANOVA (P = 0.655, F4,21 = 0.618)).
The remaining number of TH-reactive cells following in-
jection of 2 × 10 μg 6-OHDA (35% ± 4% at 2 weeks and
32% ± 7% at 4 weeks) was significantly lower as com-
pared to intact rats (92% ± 9%) and as compared to the
8-μg lesion (66% ± 8% at 2 weeks and 70% ± 7% at 4
weeks) at both 2 and 4 weeks post-lesion (TH-reactive
cell number in the left side as compared to the right
side, one-way ANOVA (P < 0.001, F4,22 = 12.479), Tukey
post hoc test, n = 4 to 5 per group) (Figure 2D).
When estimating the density of TH- and DAT-reactive
fibers in the rat striatum, the two different doses of
6-OHDA resulted in highly significant unilateral de-
crease in the striatal fiber density at both 2 and 4 weeks
post-lesion as compared to the intact rat striatum (one-
way ANOVA (P < 0.001, F4,22 = 32.564 (TH) and F4,22 =
52.435 (DAT)) and Tukey post hoc test, n = 4 to 5
per group) (Figure 2B,C; representative pictures in
Figure 1C,D). The extent of TH or DAT fiber density
loss did not differ between the lesion groups (approxi-
mately 72% to 77% loss following 8 μg 6-OHDA and
86% to 90% following 2 × 10 μg 6-OHDA). No clear
progression of the lesion could be seen in either
TH-reactive cell counts or TH- or DAT-reactive fiber
density measurements.Correlations
As expected, a high degree of positive correlation was
found between the striatal DAT binding of [123I]β-CIT
and measurements of TH- and DAT-reactive fiber dens-
ities in the rat striatum (Pearson correlation, P < 0.0001
at both time points) (Figure 3). Results from [123I]β-CIT
SPECT/CT showed also high positive correlation to TH-
Figure 2 Unilateral 6-OHDA-induced changes in [123I]β-CIT
SPECT/CT and immunohistochemical findings. All results are
presented as percentage of the lesioned/left side versus the intact/
right side. (A) The 6-OHDA injections caused a significant decrease
in striatal [123I]β-CIT uptake as compared to intact rats at both 2 and
4 weeks post-lesion. Furthermore, the two different lesions (8 and 2
× 10 μg) could be distinguished with [123I]β-CIT SPECT/CT.
Intrastriatal injection of 8 or 2 × 10 μg 6-OHDA resulted in extensive
loss of (B) DAT- and (C) TH-immunoreactive fibers in the striatum,
but there was no significant difference between the two lesion
groups. However, when counting (D) TH-reactive cells in the
substantia nigra pars compacta, the cell loss significantly differed
between the lesion types. All results are shown as mean ± SEM. ***P
< 0.001 as compared to intact rats; #P < 0.05, ##P < 0.01, and ###P <
0.001 as compared to 8-μg 6-OHDA lesion group (one-way ANOVA
followed by Tukey post hoc test, n = 4 to 5 per group).
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(Figure 3). At 4 weeks post-lesion, the amphetamine-
induced rotation asymmetry showed moderate negative
correlation with the other measurements, while at 2
weeks post-lesion no correlations could be found
between ipsilateral turning behavior and other data
(Table 2).
Discussion
The aim of our study was to estimate how well in vivo
[123I]β-CIT SPECT/CT can discriminate the severity of
dopaminergic dysfunction initiated by different intras-
triatal 6-OHDA injections in rats. The unilateral partial
6-OHDA lesion model of PD has been widely used in
pre-clinical studies of therapeutic interventions, but to
our knowledge, the model has not yet been evaluated in
both dose- and time-dependent manner with small-
animal SPECT/CT using the DAT ligand [123I]β-CIT.
Our results show that [123I]β-CIT SPECT/CT can reli-
ably be used to distinguish between single- and two-site
intrastriatal 6-OHDA injections and that the striatal
binding of [123I]β-CIT correlates well with immunohisto-
chemical findings.
Radioligands used for imaging in PD research focus on
the dopaminergic system (for review, see [23]). Common
tracers are [18F]L-3,4-dihydroxyphenylalanine (DOPA),
that give an estimate of dopamine synthesis and
radioligands with affinity for proteins important for the
dopaminergic transmission (e.g., DAT, D2 receptor, ves-
icular monoamine transporter type 2). In a recent study,
Kyono et al. [25] showed that PET detection of striatal
uptake of [18F]FDOPA, after inhibition of aromatic L-
amino acid decarboxylase and catechol-O-methyltrans-
ferase, is significantly correlated to striatal dopamine
levels in the partially 6-OHDA-lesioned rat brain. They
did four-site striatal 6-OHDA lesions of a total of 7, 14,
or 28 μg 6-OHDA. The [18F]FDOPA uptake was signifi-
cantly reduced in all three 6-OHDA groups as compared
to vehicle-injected rats, but there was no significant dif-
ference in [18F]FDOPA uptake between the different 6-
OHDA lesion groups using six animals per group.
Uptake of DOPA (which includes transport, decarboxyl-
ation, and storage) can be affected by compensatory
mechanisms in PD and PD models, leading to changes
in the turnover [26,27]. In a study by Forsback et al.
[28], the measured uptake of [18F]FDOPA showed less
sensitivity and weaker correlation to nigral cell loss than
the DAT tracer [18F]2-β-carbomethoxy-3β-(4-fluorophe-
nyl)tropane ([18F]CFT) in an ex vivo study of 6-OHDA
-lesioned rats. Compared to β-CIT, CFT is more select-
ive for DAT since β-CIT also has affinity for the sero-
tonin transporter (SERT) [29,30].
Most of the studies examining DAT binding in vivo
have been conducted on rats that have received a
Table 2 Correlations between different measurements
SPECT Rotations TH cells TH fibers DAT fibers
2 weeks SPECT 1 −0.485 0.794 0.965 0.977
P > 0.05 P < 0.005 P < 0.0001 P < 0.0001
Rotations - 1 0.089 0.462 0.499
P > 0.05 P > 0.05 P > 0.05
TH cells - - 1 0.724 0.752
P < 0.01 P < 0.005
TH fibers - - - 1 0.981
P < 0.0001
DAT fibers - - - - 1
4 weeks SPECT 1 −0.538 0.838 0.911 0.936
P < 0.05 P < 0.0001 P < 0.0001 P < 0.0001
Rotations - 1 0.754 0.656 0.630
P < 0.005 P < 0.05 P < 0.05
TH cells - - 1 0.731 0.769
P < 0.005 P < 0.005
TH fibers - - - 1 0.985
P < 0.0001
DAT fibers - - - - 1
Correlation coefficients (italic numbers) and statistical significance (P) were determined with Pearson correlation (n = 12 to 13 at 2 weeks post-lesion, and n = 14
at 4 weeks post-lesion).
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[13-18,20-22]. In these studies, information about corre-
lations between DAT binding and immunohistochemical
findings are largely lacking, and immunohistochemistry
has mainly been used as a tool to confirm the dopamin-
ergic lesion after image acquisition. Unilateral injection
of 8 μg 6-OHDA into the MFB led to an approximately
59% decrease in ipsilateral binding of [123I]β-CIT in the
striatum, and the imaging data were highly correlated to
TH-reactive cell counts in the SN [14]. When the same
amount of 6-OHDA was injected into the SN, an ap-
proximately 29% decrease in striatal DAT binding of
[123I]-N-ω-fluoropropyl-CIT ([123I]FP-CIT) was observed
[13]. Injection of a larger dose of 6-OHDA (24 μg) lead
to a 74% decrease in the [123I]FP-CIT binding [15].
In studies using PET cameras and tracers, decreases in
striatal DAT binding ranging from 33% to 85% have
been reported following injection of 8 μg 6-OHDA to
the MFB of rats [17,20-22]. In addition, Inaji [20] and
Pellegrino [21] and their co-workers showed that the de-
crease in binding was significantly correlated to drug-
induced rotational behavior. In the SN 6-OHDA lesion
model, ipsilateral DAT binding was decreased by 50%
and 65% to 85% following injection of 4 μg [16] and 8
μg 6-OHDA [18], respectively. Moreover, Hume and co-
workers [16] showed that the unilateral 6-OHDA injec-
tion did not affect the contralateral DAT binding despitethe compensatory changes that are known to take place
in the 6-OHDA model [5]. However, Van Camp et al.
[15] reported a somewhat higher (although not signifi-
cant) striatal activity of [123I]FP-CIT in the contralateral
side of 6-OHDA-lesioned rats as compared to intact
animals. When comparing the right (intact) side of
6-OHDA-treated and intact animals, we did not see any
changes in striatal [123I]β-CIT binding, indicating that
possible compensatory mechanisms did not affect the
DAT binding activity in our assay.
Using the partial lesion model, with intrastriatal injec-
tion of 4 × 6 μg 6-OHDA, Cicchetti and co-workers [19]
observed an approximately 65% decrease in striatal [11C]
CFT uptake, while the DAT binding was not affected by
a sham lesion. Sun et al. [31] reported a 24% decrease in
[11C]CFT activity ex vivo in the ipsilateral striatum fol-
lowing intrastriatal injection of a total of 28 μg (4 × 7
μg) 6-OHDA. This is in line with our study in which
intrastriatal injection of 2 × 10 μg resulted in an ap-
proximately 30% decrease in DAT density measured as
the uptake of [123I]β-CIT. The loss of DAT (and TH)-
immunoreactive fiber density in the striatum was much
more pronounced showing a decrease of approximately
86% to 90% in the lesioned side as compared to the
contralateral side. The difference in DAT density
measured by the uptake of [123I]β-CIT and DAT-
immunoreactive fiber density is probably due to
Figure 3 Correlations between [123I]β-CIT SPECT/CT and immunohistochemical and behavioral data at 2 and 4 weeks post-lesion.
Striatal binding of [123I]β-CIT showed high correlation to striatal (A) DAT- and (B) TH-reactive fiber densities and (C) nigral TH-reactive cell
numbers at both time points. At 4 weeks, [123I]β-CIT SPECT/CT correlated moderately to the amount of (D) amphetamine-induced rotations,
whereas no significant correlation was found at 2 weeks post-lesion. Correlation coefficients (r) and statistical significance (P) were determined
with Pearson correlation test (n = 12 (2 weeks) and n = 14 (4 weeks)).
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versus whole striatum).
Methodological issues may also explain why the line
plots from the correlation analysis did not intercept with
zero in the xy-axis. Another reason for this could be stri-
atal binding of [123I]β-CIT (specific or non-specific) not
related to DAT, e.g., [123I]β-CIT has also affinity to SERT[29,30]. In the rat striatum, DAT concentration is several
folds higher than the concentration of SERT, and in nor-
mal healthy rat, striatal tissue binding of [123I]β-CIT can
be considered to be mediated mainly by DAT [30]. Even
though SERT binding activity is decreased in the rat
6-OHDA model [32], there may still be a change in the
proportion of striatal DAT versus SERT binding of
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served changes in the non-specific background signal
from [11C]-methylphenidate (DAT tracer) in the stri-
atum of unilaterally 6-OHDA-lesioned rats. When com-
pared to the reference region, additional non-specific
background signal was detected from the striatum that
was almost fully denervated by 6-OHDA injection. This
increase in the background signal in the lesioned stri-
atum could interfere with the evaluation of the degree of
denervation and may cause over-estimation of striatal
DAT density and function.
No progression of the lesion could be seen during 4
weeks with any of the used measurement methods. This
is in line with previous studies that have shown that de-
generation of dopaminergic terminals happens mainly
during the first week post-lesion and is complete within
3 weeks after intrastriatal injection of 6-OHDA [8,34]. In
the partial 6-OHDA lesion model, the onset of cell death
in the SNpc starts between 1 and 2 weeks post-lesion
[8,35]. When nigral dopaminergic cells are labeled pre-
lesioning (e.g., retrograde labeling with fluoro-gold), the
cell loss following intrastriatal injection of 6-OHDA
continues to progress for an extensive period of time
(>4 weeks) [8]. However, the expression of TH is highly
regulated, and there is an acute repression of TH pheno-
type following 6-OHDA injection resulting in maximum
loss of nigral TH-immunoreactive neurons at already 2
weeks post-injection [8]. TH immunohistochemistry can
therefore be considered to be a reliable marker for DA cell
loss starting from approximately 4 weeks post-lesion.
A great advantage with in vivo [123I]β-CIT SPECT/CT
to more conventional methods is the possibility to follow
repeatedly the condition of the midbrain dopaminergic
system in living animals. To our knowledge, the present
study is the first to assess DAT binding in the partially
6-OHDA-lesioned rat, using small-animal SPECT/CT
imaging. With our nanoSPECT/CT system, the test-
retest variability was in a recent study of striatal [123I]β-
CIT binding in mice defined to be 9% [36]. Thus, this
methodology is suggested to be capable of accurate and
repeatable measurement of DAT binding using [123I]-β-
CIT. In PD research, continuous evaluation of the ani-
mals is usually done by monitoring motor function in
different behavioral test settings. The most sensitive be-
havioral test used for unilaterally lesioned rats is the de-
tection of amphetamine-induced rotational asymmetry
that can react to a 40% to 50% decrease in striatal dopa-
mine levels and 30% to 50% loss of nigral cells in the
SNpc [6]. Criticism of the test concerns the irrelevance
to motor symptoms seen in PD and the fact that the test
requires administration of a drug (dopamine agonist) to
induce the behavior (for review, see [37]). Even if it is a
sensitive test, it has also been observed that the degree
of rotation asymmetry does not necessarily correlatewith the degree of striatal dopamine depletion and dopa-
minergic denervation [6,37]. This is also seen in our
study in which, at 2 weeks post-lesion, rats lesioned with
8 μg 6-OHDA showed higher amount of drug-induced
rotations than rats lesioned with 2 × 10 μg 6-OHDA,
even though other analyses indicated that 2 × 10 μg
6-OHDA resulted in a significantly bigger lesion.
Compared to the amphetamine-induced rotational
test, many other tests used to evaluate motor function in
6-OHDA-lesioned rats require more extensive dopamin-
ergic denervation [6] and are therefore not useful for the
detection of very limited loss of dopamine neurons. In
our hands, an intrastriatal injection of 8 μg 6-OHDA
resulted in a 30% reduction in TH-positive cells in the
SNpc. This is approximately the same extent of cell loss
that has been estimated to be found at the time of onset
of motor symptoms in Parkinson's disease (discussed in
[38]). As diagnostic procedures improve, it would be im-
portant to be able to study also lesions of smaller magni-
tude to evaluate the effect of new neuroprotective
treatments aimed at this stage of the disease. Our work
shows that in vivo [123I]β-CIT SPECT/CT could be use-
ful for this purpose.
Neuronal compensation mechanisms [5,7,27] and spon-
taneous recovery of motor function despite no improve-
ment or re-innervation of the dopaminergic pathway are
other problems that can affect the outcome of some be-
havioral test (discussed in [37]). This may explain the
inconsistency in the amount of ipsilateral amphetamine-
induced rotations in our study showing a decrease in the
extent of rotational asymmetry in the 8-μg lesion group
between 2 and 4 weeks post-lesion. Obviously, the over-
interpretation of results could be partly avoided by the use
of in vivo [123I]β-CIT SPECT/CT as a complement to be-
havioral tests in animal PD models. Compensatory mecha-
nisms should, of course, also be taken into account in
SPECT/CT analyses of dopaminergic neurons since the
results can be affected by changes in DAT expression,
dopamine turnover, and axonal sprouting. Last but not
least, behavioral tests tend to result in rather big inter-
individual variations and require therefore often numerous
animals before differences between treatment groups can
reliably be detected. Our work shows that with groups of
only four to five animals, [123I]β-CIT SPECT/CT can give
statistically significant differences in striatal [123I]β-CIT
uptake between two different partial lesions of the dopa-
minergic system. The only other measurement that could
discriminate between the two different lesions was loss of
nigral TH-reactive cells.
Conclusions
We report here the use of [123I]β-CIT SPECT/CT in
evaluating the unilateral partial 6-OHDA lesion model
in rats. Results from [123I]β-CIT SPECT/CT showed a
Bäck et al. EJNMMI Research 2013, 3:46 Page 9 of 10
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could reliably be used to estimate the severity of the 6-
OHDA-induced dopaminergic lesion, showing numerous
advantages compared to conventional analysis methods.
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